Table 3.

UV and UNaV relative to intake

	Males	Females	2-Way ANOVA
UV (mL)/water intake (mL) inactive (n = 12)
Baseline	1.01 ± 0.14	1.19 ± 0.16	Psex = 0.0005, Ptime = 0.01, Pinteraction = 0.06
0–2 h Post-ZT0 injection	1.88 ± 0.29†	0.95 ± 0.14*
2–6 h	2.26 ± 0.23†	1.40 ± 0.19*
6–12 h	1.57 ± 0.37	0.78 ± 0.24
UV (mL)/water intake (mL) active (n = 8)
Baseline	0.29 ± 0.03	0.27 ± 0.04	Psex = 0.04, Ptime = 0.0005, Pinteraction = 0.3
0–2 h Post-ZT12 injection	0.57 ± 0.07†	0.39 ± 0.05
2–6 h	0.64 ± 0.09†	0.47 ± 0.11
6–12 h	0.37 ± 0.04	0.37 ± 0.05
UNaV (mEq)/Na+ intake (mg) inactive (n = 12)
Baseline	0.30 ± 0.12	0.14 ± 0.05	Psex = 0.006, Ptime < 0.0001, Pinteraction = 0.1
0–2 h Post-ZT0 injection	1.18 ± 0.59	0.57 ± 0.19
2–6 h	2.37 ± 0.92†	0.97 ± 0.18*
6–12 h	0.25 ± 0.12	0.07 ± 0.04
UNaV (mEq)/Na+ intake (mg) active (n = 8)
Baseline	0.02 ± 0.00†	0.02 ± 0.00†	Psex = 0.2, Ptime < 0.0001, Pinteraction = 0.8
0–2 h Post-injection	0.10 ± 0.01†	0.09 ± 0.02†
2–6 h	0.10 ± 0.02	0.08 ± 0.01
6–12 h	0.03 ± 0.01	0.02 ± 0.01

Data presented as means ± SE. UNaV, Na⁺ excretion; UV, urine flow rate; ZT0 and ZT12, Zeitgeber time 0 and 12, respectively.

^*P < 0.05 vs. males

and

^†P < 0.05 vs. baseline, Sidak’s multiple-comparisons test.